- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
Détention brevets de la classe C07K 14/715
Brevets de cette classe: 2542
Historique des publications depuis 10 ans
|
126
|
115
|
208
|
183
|
226
|
266
|
260
|
294
|
256
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 3974 |
88 |
| Altor BioScience, LLC | 71 |
49 |
| Xencor, Inc. | 395 |
40 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2827 |
36 |
| Vib VZW | 844 |
26 |
| The Board of Trustees of the Leland Stanford Junior University | 6226 |
25 |
| The Trustees of the University of Pennsylvania | 4251 |
25 |
| Cytune Pharma | 39 |
25 |
| National University of Singapore | 2359 |
25 |
| Amgen Inc. | 3894 |
23 |
| Universiteit Gent | 1313 |
23 |
| The Regents of the University of California | 19479 |
21 |
| Singapore Health Services Pte Ltd | 455 |
21 |
| Immunitybio, Inc. | 263 |
21 |
| Coherus Biosciences, Inc. | 139 |
19 |
| Novartis AG | 11297 |
18 |
| Bristol-myers Squibb Company | 4886 |
18 |
| Autolus Limited | 246 |
18 |
| Regents of the University of Minnesota | 2671 |
17 |
| Askgene Pharma, Inc. | 46 |
16 |
| Autres propriétaires | 1988 |